Uvax Bio, LLC

Uvax Bio is a biotechnology company focused on developing innovative prophylactic vaccines to combat infectious diseases, employing advanced technology for better health outcomes. Established in 2018 in Delaware, US, Uvax Bio specializes in vaccine development aimed at infectious diseases. The company has not undergone any known pivots or changes in business operations. Uvax Bio has completed 1 deal to date, with its most recent funding round occurring on March 26, 2025.

They raised USD 2. 6 mn in funding from Coalition for Epidemic Preparedness Innovations, bringing their total amount raised to USD 2. 6 mn. Uvax Bio specializes in the development and commercialization of prophylactic vaccines targeting infectious diseases, leveraging its proprietary 1c-SA p NP® platform technology.

The company’s core product offerings focus on innovative vaccine solutions, particularly in the realm of HIV-1, where they have finalized vaccine construct designs and are preparing candidates for Phase 1 clinical trials. Uvax Bio aims to address unmet public health needs by utilizing rational antigen design and protein engineering to create virus-like particle vaccines, which serve as a robust defense against infectious threats. The end users of these products primarily include healthcare providers, public health organizations, and potentially affected populations in global markets where HIV-1 and other infectious diseases pose significant health challenges. Uvax Bio's revenue model is structured around direct partnerships and contracts with government bodies, research institutions, and healthcare organizations interested in deploying their innovative vaccine solutions.

The company engages in business transactions through strategic collaborations, particularly with the National Institutes of Health (NIH), which has sponsored a Phase 1 clinical trial for their HIV-1 vaccine candidates. By focusing on B2B relationships, Uvax Bio ensures that its vaccine products reach healthcare providers and, ultimately, end-users in a streamlined manner. Revenue streams are generated through licensing agreements, grant funding, and potential future sales of vaccine products, reflecting a commitment to propelling public health forward while addressing critical infectious disease challenges. In March 2025, Uvax Bio raised USD 2.

6 mn in venture funding, which will be utilized to develop a preventive vaccine for Middle East Respiratory Syndrome (MERS). The company plans to launch this new vaccine product as part of its commitment to tackling severe infectious diseases. Additionally, Uvax Bio is targeting expansion into global markets where infectious diseases are prevalent, leveraging its innovative technologies to meet public health challenges. The funding will support these initiatives by facilitating research and development activities necessary for product advancement.